Bile duct cancer (cholangiocarcinoma) is diagnosed through a combination of blood tests, imaging scans, and tissue sampling. No single test can confirm it on its own, and the process often involves several steps because bile duct tumors are notoriously difficult to distinguish from benign conditions like inflammation or gallstones. Here’s what each step involves and what to expect.
Blood Tests and Tumor Markers
The diagnostic workup typically starts with blood tests. Liver function tests check for elevated bilirubin and liver enzymes, which signal that something is blocking or damaging the bile ducts. These results aren’t specific to cancer, but they flag the need for further investigation.
Two tumor markers play a role in diagnosis. CA 19-9 is elevated in up to 85% of cholangiocarcinoma cases, with median levels around 103 U/mL compared to a normal reference value below 3 U/mL. CEA, another tumor marker, is elevated in roughly 30% of cases. Neither marker is reliable enough to confirm cancer alone. CA 19-9 can rise in response to bile duct infections, pancreatitis, and other non-cancerous conditions. But when levels are very high, especially alongside suspicious imaging, they strengthen the case for cancer and can also help predict how advanced the disease is.
Imaging: Ultrasound, CT, and MRI
Abdominal ultrasound is usually the first imaging test because it’s quick and noninvasive. It can reveal dilated bile ducts, which suggest a blockage, and sometimes shows a mass. But ultrasound has limited resolution for the bile ducts themselves, so it’s typically followed by more detailed scans.
CT scans with contrast dye provide a clearer picture of the tumor’s size, location, and whether it has spread to nearby blood vessels, lymph nodes, or the liver. MRI paired with a specialized technique called MRCP (magnetic resonance cholangiopancreatography) is particularly valuable. MRCP creates detailed images of the bile duct system without requiring any instruments to enter the body. It detects bile duct strictures (narrowings) with 91% sensitivity and 98% specificity, and its overall accuracy for identifying bile duct abnormalities is around 85%. For many patients, MRCP is the key imaging step that maps out where the blockage is and helps doctors plan the next move.
ERCP: Imaging and Tissue Sampling Combined
ERCP (endoscopic retrograde cholangiopancreatography) is considered the gold standard for visualizing the bile ducts from the inside. A flexible scope is passed through your mouth, down through the stomach, and into the upper part of the small intestine where the bile duct opens. Contrast dye is injected into the ducts, and X-rays capture detailed images of any narrowing or blockage.
What makes ERCP especially useful is that it doubles as a tissue-collection tool. During the procedure, doctors can brush the inside of the duct to collect cells (brush cytology) or use tiny forceps to take a small tissue sample (forceps biopsy). These samples are then examined under a microscope. Brush cytology has a sensitivity ranging from 30% to 78%, and forceps biopsy ranges from 29% to 81%. Those numbers might sound low, but when the result is positive, it’s extremely reliable: specificity reaches nearly 100%, meaning a positive result almost certainly confirms cancer.
ERCP also allows doctors to place a stent during the same session to relieve a bile duct blockage, which can ease jaundice and itching while the full diagnosis is finalized.
What ERCP Feels Like
You’ll be asked not to eat or drink for up to 8 hours beforehand. Most people receive IV sedation to stay relaxed and comfortable, though general anesthesia is used in some cases. The procedure itself usually takes 30 to 60 minutes. Afterward, expect to stay at the hospital or outpatient center for 2 to 6 hours while the sedation wears off. Your doctor will likely have you stick to clear liquids for 4 to 6 hours, with some people waiting a full 24 hours before returning to solid food.
EUS-FNA: When Standard Biopsies Fall Short
If ERCP-based tissue sampling doesn’t provide a clear answer, or if the tumor is located outside the duct wall where brushing can’t reach, doctors may turn to EUS-FNA (endoscopic ultrasound-guided fine needle aspiration). This involves a scope with an ultrasound probe at the tip that can visualize the tumor through the wall of the stomach or intestine and guide a needle directly into it.
EUS-FNA has a sensitivity of about 75% to 76% and a specificity of 100% for malignant bile duct obstructions. It performs better than standard ERCP sampling for tumors that press on the duct from outside rather than growing within it. One study found ERCP-based sampling was 82.4% accurate for tumors inside the duct but only 54.8% accurate for tumors outside it, which is exactly where EUS-FNA excels.
When both ERCP-based sampling and EUS-FNA are performed in the same session, the combined sensitivity jumps to 86% with an accuracy of 96.5%. This is why many specialized centers use both techniques together when a definitive diagnosis proves elusive.
Why Diagnosis Can Be Difficult
Bile duct cancer is one of the hardest cancers to confirm, partly because it can look almost identical to benign conditions on imaging. People with primary sclerosing cholangitis, a chronic inflammatory disease of the bile ducts, face a particular challenge. Both PSC and cholangiocarcinoma cause bile duct strictures and irregularities that look similar on imaging, making it very difficult to tell whether a new narrowing is caused by inflammation or a tumor. Even with imaging and tissue sampling combined, overall diagnostic accuracy for bile duct abnormalities hovers around 70% to 80%.
This is why doctors often rely on the full picture: blood work, imaging findings, tumor marker levels, and tissue samples all considered together, rather than any single test result.
Staging: Determining How Far It Has Spread
Once bile duct cancer is confirmed, staging determines how far it has progressed. The staging system depends on where the cancer started, because tumors inside the liver, at the junction where the ducts meet (perihilar), and in the lower bile duct near the intestine each behave differently.
For intrahepatic bile duct cancer (inside the liver), early stages are defined by tumor size. Stage IA means the tumor is 5 centimeters or smaller, while stage IB means it’s larger than 5 cm. By stage II, the cancer has grown into a blood vessel or formed multiple tumors. Stage IIIA involves spread through the liver’s outer lining, and stage IIIB means nearby organs or lymph nodes are affected. Stage IV indicates spread to distant sites like the lungs or bones.
For perihilar bile duct cancer, staging tracks how deeply the tumor has invaded the duct wall and whether it involves critical blood vessels. Stage I is confined to the duct wall layers. Stage II means the cancer has pushed through the wall into nearby fat or liver tissue. Stage III involves major blood vessels or lymph nodes, and stage IV means spread to four or more lymph nodes or distant organs.
For distal bile duct cancer, staging is based on how many millimeters the tumor has penetrated through the duct wall. Stage I means fewer than 5 millimeters of invasion. Stage II involves deeper invasion or spread to a few nearby lymph nodes, and stage III means four or more lymph nodes are involved.
Staging is determined using the imaging already done during diagnosis (CT, MRI) along with any additional scans needed, such as PET scans to check for distant spread. The stage directly shapes treatment decisions, including whether surgery to remove the tumor is an option.
Genomic Profiling After Diagnosis
Once bile duct cancer is confirmed, doctors increasingly test the tumor for specific genetic mutations that can guide treatment. Roughly 10% to 15% of intrahepatic cholangiocarcinomas carry FGFR2 fusions, and others harbor IDH1 mutations. Both of these have FDA-approved targeted therapies available for patients whose cancer has these alterations. HER2-positive bile duct cancers also now have approved treatment options.
This genomic testing can be done on the original biopsy tissue or, when tissue is limited, through a blood draw that analyzes tumor DNA circulating in the bloodstream. Studies have shown strong agreement between blood-based and tissue-based genomic results in advanced bile duct cancer, making blood-based testing a practical backup when obtaining more tissue would be difficult or risky.